Cochrane · systematic review · CD006923
Regular treatment with formoterol for chronic asthma: serious adverse events
Cates, CJ, Cates, MJ · Cochrane Database of Systematic Reviews · 2012 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
5
No studies
1
Included studies
NR
No studies 1 · 16.7%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 3 · 50%High 2 · 33.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlySummary of findings ‐ SAE all ages
Population: patients with chronic asthma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
SAEs ‐ formoterol versus placebo ( | OR 1.57 [1.05, 2.37] | 19 studies · 6646 participants | High |
SAEs ‐ formoterol versus salbutamol ( | OR 0.72 [0.37, 1.43] | 9 studies · 2119 participants | Moderate |
Summary of findings ‐ mortality (all‐cause)
Population: patients with chronic asthma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality (all‐cause) ‐ formoterol versus placebo ( | OR 1.52 [0.24, 9.71] | 14 studies · 5463 participants | Moderate |
Mortality (all‐cause) ‐ formoterol versus salbutamol ( | OR 0.5 [0.03, 8.05] | 6 studies · 1418 participants | Moderate |
Summary of findings ‐ SAE children
Population: patients with chronic asthma (children)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
SAEs ‐ formoterol versus placebo ( | OR 2.82 [1.16, 6.83] | 5 studies · 1335 participants | High |
SAEs ‐ formoterol versus salbutamol | no estimate extracted | NR | No studies |
Summary of findings ‐ SAE all ages
Population: patients with chronic asthma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Serious Adverse Events ‐ formoterol versus placebo ( | OR 1.57 [1.05, 2.37] | 19 studies · 6646 participants | High |
Serious Adverse Events ‐ formoterol versus salbutamol ( | OR 0.72 [0.37, 1.43] | 9 studies · 2119 participants | Moderate |
Summary of findings ‐ mortality (all cause)
Population: patients with chronic asthma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality (all cause) ‐ formoterol versus placebo ( | OR 1.52 [0.24, 9.71] | 14 studies · 5463 participants | Moderate |
Mortality (all‐cause) ‐ formoterol versus salbutamol ( | OR 0.5 [0.03, 8.05] | 6 studies · 1418 participants | Moderate |
Summary of findings ‐ SAE children
Population: patients with chronic asthma (children)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Serious Adverse Events ‐ formoterol versus placebo ( | OR 2.82 [1.16, 6.83] | 5 studies · 1335 participants | High |
Serious Adverse Events ‐ formoterol versus salbutamol | no estimate extracted | NR | No studies |